Biohaven Ltd
BHVN
查看详细走势图
10.720USD
+0.220+2.10%
收盘 12/24, 13:00（美东）报价延迟15分钟
1.13B总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+2.10%
5天
-1.38%
1月
+10.74%
6月
-27.42%
今年开始到现在
-71.30%
1年
-70.01%
查看详细走势图
TradingKey Biohaven Ltd股票评分
单位: USD 更新时间: 2025-10-27操作建议
当前估值合理，机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价max_target_price。目前股价在压力位和支撑位之间，可以做区间波段操作。
Biohaven Ltd评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
18
位分析师
买入
评级
19.563
目标均价
+85.60%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Biohaven Ltd亮点
亮点风险
Biohaven Ltd. is a biopharmaceutical company focused on the discovery, development and commercialization of treatments in key therapeutic areas, including immunology, neuroscience, and oncology. It is advancing its portfolio of therapeutics, leveraging its drug development experience and multiple proprietary drug development platforms. Its clinical and preclinical programs include Kv7 ion channel modulation for epilepsy and mood disorders; extracellular protein degradation for immunological diseases; TRPM3 antagonism for migraine and neuropathic pain; TYK2/JAK1 inhibition for neuroinflammatory disorders; glutamate modulation for obsessive-compulsive disorder (OCD) and spinocerebellar ataxia (SCA); myostatin inhibition for neuromuscular and metabolic diseases, including spinal muscular atrophy (SMA) and obesity; antibody recruiting bispecific molecules; and antibody drug conjugates for cancer. Its advanced product candidate from its glutamate receptor antagonist platform is troriluzole.
利润高增长
公司净利润处于行业前列，最新年度总收入0.00美元
估值合理
公司最新PE估值-2.33，处于3年历史合理位
机构减仓
最新机构持股87.60M股，环比减少13.13%
CI 精选加拿大股票基金持仓
明星投资者CI 精选加拿大股票基金持仓，最新持仓市值429.00
Biohaven Ltd新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Biohaven Ltd简介
Biohaven Ltd. is a biopharmaceutical company focused on the discovery, development and commercialization of treatments in key therapeutic areas, including immunology, neuroscience, and oncology. It is advancing its portfolio of therapeutics, leveraging its drug development experience and multiple proprietary drug development platforms. Its clinical and preclinical programs include Kv7 ion channel modulation for epilepsy and mood disorders; extracellular protein degradation for immunological diseases; TRPM3 antagonism for migraine and neuropathic pain; TYK2/JAK1 inhibition for neuroinflammatory disorders; glutamate modulation for obsessive-compulsive disorder (OCD) and spinocerebellar ataxia (SCA); myostatin inhibition for neuromuscular and metabolic diseases, including spinal muscular atrophy (SMA) and obesity; antibody recruiting bispecific molecules; and antibody drug conjugates for cancer. Its advanced product candidate from its glutamate receptor antagonist platform is troriluzole.
公司代码BHVN
公司Biohaven Ltd
CEOCoric (Vlad)
网址https://www.biohaven.com/
常见问题
Biohaven Ltd(BHVN)的当前股价是多少？
Biohaven Ltd(BHVN)的当前股价是 10.720。
Biohaven Ltd的股票代码是什么？
Biohaven Ltd的股票代码是BHVN。
Biohaven Ltd股票的52周最高点是多少？
Biohaven Ltd股票的52周最高点是44.280。
Biohaven Ltd股票的52周最低点是多少？
Biohaven Ltd股票的52周最低点是7.480。
Biohaven Ltd的市值是多少？
Biohaven Ltd的市值是1.13B。
Biohaven Ltd的净利润是多少？
Biohaven Ltd的净利润为-846.42M。
现在Biohaven Ltd(BHVN)的股票是买入、持有还是卖出？
根据分析师评级，Biohaven Ltd(BHVN)的总体评级为买入，目标价格为19.563。
Biohaven Ltd(BHVN)股票的每股收益（EPS TTM）是多少
Biohaven Ltd(BHVN)股票的每股收益（EPS TTM）是-7.515。
相关品种
